GlassScriptPhysician profile
Jennifer Nemeth
NPI 1740097302
$801.68
in general payments reported to CMS, 2019-2025
13 companies · $802 in 2025
The $802 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749 · Education: $52.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.35 |
| Education | $52.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $338.03 | 2025 | Fasenra, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $171.12 | 2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $49.26 | 2025 | Neffy |
| Csl Behring | $46.75 | 2025 | Hizentra |
| Glaxosmithkline, LLC. | $40.35 | 2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $24.16 | 2025 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $22.95 | 2025 | |
| Lilly USA, LLC | $21.91 | 2025 | Ebglyss |
| Genzyme Corporation | $20.04 | 2025 | |
| Abbvie INC. | $18.20 | 2025 | |
| Optinose US, INC. | $18.05 | 2025 | |
| Incyte Corporation | $15.67 | 2025 | Opzelura |
| Blueprint Medicines Corporation | $15.19 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Nemeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.